Literature DB >> 28956295

Response to 'Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"'.

Inigo Bermejo1, Paul Tappenden2, Ji-Hee Youn3.   

Abstract

Mesh：

Year:  2017        PMID： 28956295     DOI： 10.1007/s40273-017-0574-5

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  7 in total

Review 1.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Authors:  Z Philips; L Ginnelly; M Sculpher; K Claxton; S Golder; R Riemsma; N Woolacoot; J Glanville
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014

2.  Replicating Health Economic Models: Firm Foundations or a House of Cards?

Authors:  Inigo Bermejo; Paul Tappenden; Ji-Hee Youn
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

3.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

4.  Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Authors:  Christopher Bell; Jonathan Graham; Stephanie Earnshaw; Merrikay Oleen-Burkey; Jane Castelli-Haley; Kenneth Johnson
Journal:  J Manag Care Pharm       Date:  2007-04

5.  A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.

Authors:  Paul Tappenden; Shijie Ren; Rachel Archer; Rebecca Harvey; Marrissa Martyn-St James; Hasan Basarir; John Stevens; Alan Lobo; Sami Hoque
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

6.  Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"

Authors:  Emma McManus; Tracey Sach
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

7.  Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.

Authors:  Matthijs Versteegh
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981
  7 in total
  1 in total

Review 1.  Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics.

Authors:  Emma McManus; David Turner; Tracey Sach
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.